| Source | us.nlm.vsac#0.11.0:null (v4.0.1) |
| resourceType | ValueSet |
| id | 2.16.840.1.113883.3.666.5.2348 |
| canonical | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2348 |
| version | 20160331 |
| status | active |
| publisher | Lantana EH Steward |
| name | ImmunocompromisedTherapies |
| title | Immunocompromised Therapies |
| date | 2022-03-03T18:46:01-05:00 |
| experimental | false |
| Usages | (none) |
This value set contains 156 concepts
| Code | System | Display |
| 00.10 | http://hl7.org/fhir/sid/icd-9-cm | Implantation of chemotherapeutic agent |
| 00.15 | http://hl7.org/fhir/sid/icd-9-cm | High-dose infusion interleukin-2 [IL-2] |
| 17.70 | http://hl7.org/fhir/sid/icd-9-cm | Intravenous infusion of clofarabine |
| 367336001 | http://snomed.info/sct | Chemotherapy (procedure) |
| 3E00X05 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach |
| 3E00X0M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach |
| 3E01305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach |
| 3E0130M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach |
| 3E02305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Muscle, Percutaneous Approach |
| 3E0230M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach |
| 3E03002 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach |
| 3E03003 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach |
| 3E03005 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Peripheral Vein, Open Approach |
| 3E0300M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach |
| 3E0300P | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Clofarabine into Peripheral Vein, Open Approach |
| 3E03302 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach |
| 3E03303 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach |
| 3E03305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach |
| 3E0330M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach |
| 3E0330P | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach |
| 3E04002 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Central Vein, Open Approach |
| 3E04003 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach |
| 3E04005 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Central Vein, Open Approach |
| 3E0400M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach |
| 3E0400P | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Clofarabine into Central Vein, Open Approach |
| 3E04302 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach |
| 3E04303 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach |
| 3E04305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach |
| 3E0430M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach |
| 3E0430P | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Clofarabine into Central Vein, Percutaneous Approach |
| 3E05002 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach |
| 3E05003 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach |
| 3E05005 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Peripheral Artery, Open Approach |
| 3E0500M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach |
| 3E0500P | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Clofarabine into Peripheral Artery, Open Approach |
| 3E05302 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach |
| 3E05303 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach |
| 3E05305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach |
| 3E0530M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach |
| 3E0530P | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach |
| 3E06002 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Central Artery, Open Approach |
| 3E06003 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach |
| 3E06005 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Central Artery, Open Approach |
| 3E0600M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach |
| 3E0600P | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Clofarabine into Central Artery, Open Approach |
| 3E06302 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach |
| 3E06303 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach |
| 3E06305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach |
| 3E0630M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach |
| 3E0630P | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Clofarabine into Central Artery, Percutaneous Approach |
| 3E09305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Nose, Percutaneous Approach |
| 3E0930M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach |
| 3E09705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening |
| 3E0970M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening |
| 3E09X05 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Nose, External Approach |
| 3E09X0M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach |
| 3E0A305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach |
| 3E0A30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach |
| 3E0B305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Ear, Percutaneous Approach |
| 3E0B30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach |
| 3E0B705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening |
| 3E0B70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening |
| 3E0BX05 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Ear, External Approach |
| 3E0BX0M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach |
| 3E0C305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Eye, Percutaneous Approach |
| 3E0C30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach |
| 3E0C705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening |
| 3E0C70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening |
| 3E0CX05 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Eye, External Approach |
| 3E0CX0M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach |
| 3E0D305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach |
| 3E0D30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach |
| 3E0D705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0DX05 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach |
| 3E0DX0M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach |
| 3E0E305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach |
| 3E0E30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach |
| 3E0E705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening |
| 3E0E70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening |
| 3E0E805 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E80M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0F305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach |
| 3E0F30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach |
| 3E0F705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F805 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F80M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0G305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach |
| 3E0G30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach |
| 3E0G705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening |
| 3E0G70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening |
| 3E0G805 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G80M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach |
| 3E0H30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach |
| 3E0H705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening |
| 3E0H70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening |
| 3E0H805 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H80M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0J305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J805 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J80M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach |
| 3E0K30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach |
| 3E0K705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K805 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K80M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0L305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach |
| 3E0L30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach |
| 3E0L705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening |
| 3E0L70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening |
| 3E0M305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach |
| 3E0M30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach |
| 3E0M705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening |
| 3E0M70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening |
| 3E0N305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach |
| 3E0N30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach |
| 3E0N705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N805 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N80M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach |
| 3E0P30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach |
| 3E0P705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P805 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P80M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0Q305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening |
| 3E0Q70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening |
| 3E0R302 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach |
| 3E0R303 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach |
| 3E0R305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach |
| 3E0R30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach |
| 3E0S302 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach |
| 3E0S303 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach |
| 3E0S305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach |
| 3E0S30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach |
| 3E0U305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Joints, Percutaneous Approach |
| 3E0U30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach |
| 3E0V305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Bones, Percutaneous Approach |
| 3E0V30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach |
| 3E0W305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach |
| 3E0W30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach |
| 3E0Y305 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach |
| 3E0Y30M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach |
| 3E0Y705 | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening |
| 3E0Y70M | http://www.cms.gov/Medicare/Coding/ICD10 | Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening |
| 99.25 | http://hl7.org/fhir/sid/icd-9-cm | Injection or infusion of cancer chemotherapeutic substance |
| 99.28 | http://hl7.org/fhir/sid/icd-9-cm | Injection or infusion of biological response modifier [BRM] as an antineoplastic agent |
Produced 08 Sep 2023